Brief: Targovax Says Financing Of Up To NOK 300 Mln Over Three Years To Advance Its Clinical Cancer Programs & Pre-Clinical Circular RNA Platform

Circio Holding ASA

16/02/2023 05:58

Feb 16 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES FINANCING OF UP TO NOK 300M OVER THREE
YEARS
TO ADVANCE ITS CLINICAL CANCER PROGRAMS & PRE-CLINICAL CIRCULAR
RNA PLATFORM
    * TARGOVAX- FINANCING WILL BE MADE AVAILABLE THROUGH AN
INITIAL
TRANCHE OF BONDS IN TOTAL NOMINAL VALUE OF NOK 37.5M UPON EGM
APPROVAL OF AGREEMENT
    * TARGOVAX RETAINS RIGHT TO REPURCHASE UNCONVERTED BONDS AT
ANY
TIME AT 110 PERCENT OF NOMINAL VALUE
    * CONVERTIBLE BONDS WILL BE ISSUED AT 92 % OF NOMINAL VALUE
AND
THEREBY PROVIDE TARGOVAX WITH A TOTAL OF UP TO NOK 276 MILLION
IN NET CAPITAL

Source text for Eikon:  ID:nWkrbS6H9l 
Further company coverage:  TRVX.OL 
 ((Reuters.Briefs@thomsonreuters.com;;))